The DOI matches its Crossref record; 268 of the 268 references it cites were found in a registry or an index.
Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?
Abstract
To create a drug, nature's blueprints often have to be improved through semisynthesis or total synthesis (chemical postevolution). Selected contributions from industrial and academic groups highlight the arduous but rewarding path from natural products to drugs. Principle modification types for natural products are discussed herein, such as decoration, substitution, and degradation. The biological, chemical, and socioeconomic environments of antibacterial research are dealt with in context. Natural products, many from soil organisms, have provided the majority of lead structures for marketed anti‐infectives. Surprisingly, numerous “old” classes of antibacterial natural products have never been intensively explored by medicinal chemists. Nevertheless, research on antibacterial natural products is flagging. Apparently, the “old fashioned” natural products no longer fit into modern drug discovery. The handling of natural products is cumbersome, requiring nonstandardized workflows and extended timelines. Revisiting natural products with modern chemistry and target‐finding tools from biology (reversed genomics) is one option for their revival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–268 of 268
Structural Basis for Imipenem Inhibition of Class C β-Lactamases
Beadle, B. M., & Shoichet, B. K. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3978-3980.2002 · Cited by 78
Tigecycline: A Novel Glycylcycline
Rubinstein, E., & Vaughan, D. (2005) · Drugs · doi:10.2165/00003495-200565100-00002 · Cited by 76
Struktur‐Wirkungs‐Beziehungen von Oxazolidinonen: Grundlage der Entwicklung von Linezolid
Barbachyn, M. R., & Ford, C. W. (2003) · Angewandte Chemie · doi:10.1002/ange.200200528 · Cited by 76
Beyer, D., Kroll, H., Endermann, R., Schiffer, G., Siegel, S., Bauser, M., Pohlmann, J., Brands, M., Ziegelbauer, K. B., Haebich, D., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.525-532.2004 · Cited by 76
Self-citationLabischinski, H. (1992) · Medical Microbiology and Immunology · doi:10.1007/bf00198846 · Cited by 75
Total synthesis of .beta.-lactam antibiotics. VII. Total synthesis of (+-)-1-oxacephalothin
CAMA, L. D., & CHRISTENSEN, B. G. (1974) · Journal of the American Chemical Society · doi:10.1021/ja00831a049 · Cited by 74
Overview of Resistance in the 1990s
File, T. M. (1999) · CHEST Journal · doi:10.1378/chest.115.suppl_1.3s · Cited by 74
Gordon, K. A., Biedenbach, D. J., & Jones, R. N. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(03)00087-7 · Cited by 71
Proteins of the penicillin biosynthesis pathway
Schofield, C. J., Baldwin, J. E., Byford, M. F., Clifton, I. J., Hajdu, J., Hensgens, C. M. H., & Roach, P. L. (1997) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(97)80158-3 · Cited by 70
Chalker, A. F., & Lunsford, R. D. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00222-x · Cited by 68
Semi-synthetic glycopeptide antibacterials
Judice, J. K., & Pace, J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.08.067 · Cited by 68
Fischer, H., Brunner, N. A., Wieland, B., Paquette, J., Macko, L., Ziegelbauer, K. B., & Freiberg, C. (2004) · Genome Research · doi:10.1101/gr.1275704 · Cited by 65
The bacterial ribosome, a promising focus for structure-based drug design
Knowles, D., Foloppe, N., Matassova, N., & Murchie, A. I. H. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00205-9 · Cited by 65
Antimicrobial resistance among gram-positive organisms in the intensive care unit
Clark, N. M., Hershberger, E., Zervosc, M. J., & Lynch, J. P. (2003) · Current Opinion in Critical Care · doi:10.1097/00075198-200310000-00011 · Cited by 63
Der Aufbau von Vancomycin: so macht es die Natur
Hubbard, B. K., & Walsh, C. T. (2003) · Angewandte Chemie · doi:10.1002/ange.200390171 · Cited by 62
S�ssmuth, R., & Wohlleben, W. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-003-1443-z · Cited by 61
Antibiotic resistance in Staphylococcus aureus and its relevance in therapy
Bal, A. M., & Gould, I. M. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.13.2257 · Cited by 61
Recent Developments on Ketolides and Macrolides
Wu, Y.-J., & Su, W.-G. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013371671 · Cited by 61
Yuan, C., & Williams, R. M. (1997) · Journal of the American Chemical Society · doi:10.1021/ja972670j · Cited by 59
A New Approach to the Inhibition of Metallo‐β‐lactamases
SPENCER, J. M., & Walsh, T. R. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502984 · Cited by 57
KATAYAMA, N., Fukusumi, S., Funabashi, Y., et al. (1993) · The Journal of Antibiotics · doi:10.7164/antibiotics.46.606 · Cited by 57
Shull, C. A. (1935) · Botanical Gazette · doi:10.1086/334577 · Cited by 56
Peptide antibiotics of the tuberactinomycin family as inhibitors of group I intron RNA splicing
Wank, H., Rogers, J., DAVIES, J. E., & Schroeder, R. (1994) · Journal of Molecular Biology · doi:10.1016/0022-2836(94)90007-8 · Cited by 55
Mining the microbial metabolome: a new frontier for natural product lead discovery
Perić, N., & Long, P. F. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02901-5 · Cited by 53
Leeds, J. A., Schmitt, E. K., & Krastel, P. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.211 · Cited by 52
Keynote review: Disease-specific target selection: a critical first step down the right road
Roses, A. D., Burns, D. K., Chissoe, S. L., Middleton, L. T., & Jean, P. S. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03321-5 · Cited by 51
Vancomycin: Report on Treatment of Patients with Severe Staphylococcal Infections
Dutton, A. A. C., & Elmes, P. C. (1959) · BMJ · doi:10.1136/bmj.1.5130.1144 · Cited by 50
BASKER, M. J., Boon, R. J., & Hunter, P. (1980) · The Journal of Antibiotics · doi:10.7164/antibiotics.33.878 · Cited by 49
Der Einfluss bakterieller Genomik auf die Naturstoff‐Forschung
Bode, H. B., & Müller, R. (2005) · Angewandte Chemie · doi:10.1002/ange.200501080 · Cited by 47
How many genomics targets can a portfolio afford?
Betz, U. A. K. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03498-7 · Cited by 44
Kaatz, G. W. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.2.223 · Cited by 44
Milton, I. D., Hewitt, C. L., & Harwood, C. R. (1992) · FEMS Microbiology Letters · doi:10.1016/0378-1097(92)90377-z · Cited by 43
Development of drugs for antimicrobial-resistant pathogens
Powers, J. H. (2003) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200312000-00006 · Cited by 41
The Art of Fusion: From Penams and Cephems to Penems
Dalhoff, A., & Thomson, C. J. (2003) · Chemotherapy · doi:10.1159/000070616 · Cited by 41
Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents
Schuck, E. L., & Derendorf, H. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.3.361 · Cited by 41
The evolution and role of macrolides in infectious diseases
Blondeau, J. M. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.8.1131 · Cited by 40
Structural understanding of efflux-mediated drug resistance: potential routes to efflux inhibition
McKeegan, K. S., Borges-Walmsley, M. I., & Walmsley, A. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.07.002 · Cited by 39
Structural proteomics: the potential of high-throughput structure determination
Schmid, M. B. (2002) · Trends in Microbiology · doi:10.1016/s0966-842x(02)02443-5 · Cited by 39
Cephalosporins in clinical development
Page, M. G. P. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.8.973 · Cited by 37
Druggability: selecting optimized drug candidates
Sugiyama, Y. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03675-5 · Cited by 37
Structure activity relationships in lincosamide and streptogramin antibiotics
Goffic, F. L. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/16.suppl_a.13 · Cited by 36
Der Weg zu Fludelon: ein Tumortherapeutikum mit außergewöhnlichen Eigenschaften
Rivkin, A., Chou, T., & Danishefsky, S. J. (2005) · Angewandte Chemie · doi:10.1002/ange.200461751 · Cited by 35
Anthonisen, N. R. (1999) · CHEST Journal · doi:10.1378/chest.115.1.3 · Cited by 30
The structure of enopeptins A and B, novel depsipeptide antibiotics
Koshino, H., Osada, H., Yano, T., Uzawa, J., & Isono, K. (1991) · Tetrahedron Letters · doi:10.1016/0040-4039(91)80571-m · Cited by 30
Innovation: Large‐Scale Manufacture of Peptide Therapeutics by Chemical Synthesis
Bray, B. L. (2004) · ChemInform · doi:10.1002/chin.200410275 · Cited by 29
Characterization of a novel antibacterial agent that inhibits bacterial translation
DDEKER, N. B., Bahador, G., Gibbs, C. S., Mabery, E. M., WOLF, J., Xu, L., & Watson, J. (2002) · RNA · doi:10.1017/s1355838202024020 · Cited by 29
DeRyke, C. A., Maglio, D., & Nicolau, D. P. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.6.873 · Cited by 24
A New Route to Designer Antibiotics
Khosla, C., & Tang, Y. (2005) · Science · doi:10.1126/science.1111415 · Cited by 21
Glister, G. A., & Grainger, A. (1950) · The Analyst · doi:10.1039/an9507500310 · Cited by 21
How can we avoid the productivity gap?
Carney, S. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03533-6 · Cited by 20
Past and current use of clindamycin and lincomycin
Phillips, I. (1981) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/7.suppl_a.11 · Cited by 20
Is There Hope for the Prevention of Future Antimicrobial Shortages?
Gilbert, D. N., & Edwards, J. E. (2002) · Clinical Infectious Diseases · doi:10.1086/341958 · Cited by 19
Novelties in the field of macrolides
Bryskier, A. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.11.1697 · Cited by 18
Stebbing, J., Savage, P. M., Patterson, S., & Gazzard, B. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh010 · Cited by 18
Global dissemination of β2-lactamases mediating resistance to cephalosporins and carbapenems
Gootz, T. D. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.2.317 · Cited by 16
β-Lactamases and their Inhibitors: An Update
Micetich, R. G., Salama, S., Maiti, S. N., Reddy, A. P. K., & Singh, R. (2002) · Anti-Infective Agents · doi:10.2174/1568012023354901 · Cited by 15
Metallo‐β‐lactamasen: ein neuer Inhibitionsansatz
SPENCER, J. M., & Walsh, T. R. (2006) · Angewandte Chemie · doi:10.1002/ange.200502984 · Cited by 15
Trends in Exploration of Therapeutic Targets
Zheng, C. J., Han, L., Yap, C. W., Xie, B., & Chen, Y. (2005) · Drug News & Perspectives · doi:10.1358/dnp.2005.18.2.886480 · Cited by 14
PREOBRAZHENSKAYA, M. N., & Olsufyeva, E. N. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.2.141 · Cited by 14
Wilson, D. N., & Nierhaus, K. H. (2003) · Angewandte Chemie · doi:10.1002/ange.200200544 · Cited by 12
Protein synthesis as a target for antibacterial drugs: current status and future opportunities
Chopra, I. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.8.1237 · Cited by 11
Bacterial Genomics as a Potential Tool for Discovering New Antimicrobial Agents
Waterman, S. R. (2001) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200101040-00003 · Cited by 7
Oral cephalosporin antibiotics: an overview of clinical pharmacology and dermatologic applications.
Rosso, J. Q. D. (2003) · PubMed · Cited by 6
Qadri, S. M. H., KARIM, M. R., & Flournoy, D. J. (1983) · The Journal of Antibiotics · doi:10.7164/antibiotics.36.42 · Cited by 5
Alekshun, M. N. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.1.93 · Cited by 4
Beyond Genome – Proteomics: The Future of Biomedicine
Zhang, W. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.6.555 · Cited by 3
Genomic Strategies in Antibacterial Drug Discovery
Gray, C. P., & Keck, W. (2003) · CRC Press eBooks · doi:10.1201/9780203911464.ch5 · Cited by 3
(1999) · doi:10.1002/(sici)1521-3773(19990301)38:5<643::aid-anie643>3.0.co;2-g
Cited by
Antibacterial properties of nanoparticles
Hajipour, M. J., Fromm, K. M., Akbar Ashkarran, A., Jimenez de Aberasturi, D., Larramendi, I. R. D., Rojo, T., Serpooshan, V., Parak, W. J., & Mahmoudi, M. (2012) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.06.004 · Cited by 2,710
A Historical Overview of Natural Products in Drug Discovery
Dias, D. A., Urban, S., & Roessner, U. (2012) · Metabolites · doi:10.3390/metabo2020303 · Cited by 1,958
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
Electrifying Organic Synthesis
Wiebe, A., Gieshoff, T., Möhle, S., Rodrigo, E., Zirbes, M., & Waldvogel, S. R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201711060 · Cited by 1,530
Thoughts and facts about antibiotics: Where we are now and where we are heading
Bérdy, J. (2012) · The Journal of Antibiotics · doi:10.1038/ja.2012.27 · Cited by 1,165
Metadata
- Authors
- von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2006-07-31
- Volume
- 45
- Issue
- 31
- Pages
- 5072-5129
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2016567759
- Cited by
- 672
- References
- 268
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.